Skip to main content
Premium Trial:

Request an Annual Quote

Pablo Cagnoni and Tony Coles

CRISPR Therapeutics has added Pablo Cagnoni to its board of directors and has named Tony Coles chairman of the board. Cagnoni currently serves as CEO of Tizona Therapeutics and executive chairman of Blade Therapeutics. Prior to that, he held executive positions at Onyx Pharmaceuticals and Novartis Oncology. Cagnoni holds an MD from the University of Buenos Aires School of Medicine. Coles joined CRISPR Therapeutics' board in 2015 and succeeds Bradley Bolzon, managing director of Versant Ventures and founding chairman since 2013.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Whale Decline Analysis

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.